



# **Research & Development**


**Eisai Co., Ltd.**

**Executive Vice President**

**Hiroshi Yamauchi**



# . Neurology Area



# Aricept Life-

# New Projects


## 1. Under Clinical Development (U.S. & EU)

- E2007: Multiple sclerosis, **Parkinson's dyskinesia, Epilepsy**
- E2102: Central acting muscle relaxant
- E2051: Acute ischemic stroke

## 2. Preparation for Clinical Study (Japan)

- E2014: Cervical dystonia (in-licensed from Elan)

**In-**



# **Alzheimer's Disease Research Agreement with Neurogenetics Inc.**

- **Discovery of genes responsible for late onset Alzheimer's disease**
- **Eisai has rights of first negotiation and refusal.**
- **The research will be done at Neurogenetics in collaboration with Dr. R. Tanzi of the Massachusetts General Hospital and Harvard University.**





# E7070

## New Sulfonamide Derivative Cancer Agent

### Phase

- **Mono therapy**


- Colorectal cancer: Database locked (EU)
- NSCLC: Database locked (EU)
- Breast cancer: **Finished enrollment (EU)**
- Melanoma: Finished enrollment (EU)
- Head & neck cancer: **Finished enrollment (EU)**
- Renal cancer: EU)

# III. GI Area

- **Aciphex/Pariet Life-cycle Management**
  - **New Indications**
    - **GERD Maintenance**
      - Filed in Japan (January 2002)
    - ***H. pylori* eradication**
      - Filed in U.S. (January 2002)
      - **Under preparation for Phase III in Japan**
- **New Project**
  - **E3309 (*H. pylori* eradication) Phase I in EU**

# IV. E5564

## - Endotoxin antagonist -



Phase :

Strong anti-endotoxin effect confirmed

Plan for Phase

–Sepsis

–Prophylactic use of endotoxemia after  
Coronary Artery Bypass Graft Surgery

# V. Japan Projects

- **Phase**
  - **E6010 (Cleactor, pulmonary embolism): filing preparations in process**
  - **T-614 (rheumatoid arthritis, joint development with Toyama Chemical): filing preparations in process**
- **Phase**
  - **KES524 (obesity management, joint development with Abbott)**
  -

# V. Japan Projects

## Ø Phase I

### ' Oncology

- E7070 (G1 phase arresting agent)

### ' Others

- E6040 (autoimmune diseases)
- D2E7 (rheumatoid arthritis) Joint development

# Global Clinical Research System

